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Available online 2 December 2016Objective: Patients with aneurysmal subarachnoid hemorrhage (aSAH) experience highmortality andmorbidity.
Neuroinﬂammation causes brain damage expansion after aSAH. Due to the complexity of the inﬂammatory re-
sponse multiple biomarkers are needed to evaluate its' progression. We studied inﬂammatory process after
aSAH by measuring two inﬂammatory biomarkers, interleukin-6 (IL-6) and high-mobility group box 1
(HMGB1) at simultaneous time-points after aSAH.
Methods: In this prospective population-based study, IL-6 and HMGB1weremeasured in aSAH patients (n= 47)
for up to ﬁve days. Plasma concentrations of IL-6 and HMGB1 were measured at 0, 12 and 24 h after hospital ad-
mission, and thereafter daily for up to ﬁve days or until the patient was transferred from the intensive care unit
(ICU). The patients' neurological outcomes were evaluated with the modiﬁed Rankin Scale at six months after
aSAH.
Results: A high IL-6 level during the ﬁrst day after aSAH was associated with a severe initial clinical presentation
(p = 0.002) and infection during follow-up (p = 0.031). The HMGB1 level did not associate with these param-
eters. There was no correlation between IL-6 and HMGB1 levels at any time point during the follow-up. The
concentrations of IL-6 and HMGB1 were not associated with neurological outcome.
Conclusions: High initial IL-6 values seem to reﬂect the intensity of the inﬂammatory response but not the brain
damage per se. An early inﬂammatory responsemight even be beneﬁcial since although elevated IL-6 levelswere
observed in patients with a more severe initial clinical presentation, they were not associated with neurological
outcome. The lack of correlation between IL-6 and HMGB1 questions the role of macrophages in the process of
the secretion of these inﬂammatory markers after aSAH, instead pointing to the activation of alternative pro-
inﬂammatory pathways.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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HMGB11. Introduction
Despite recent advances in the management of aneurysmal sub-
arachnoid hemorrhage (aSAH), it remains a devastating disease with a
mortality approaching 50% and fewer than 60% of the survivors achiev-
ing functional independence [1]. The brain injury developing after aSAH
occurs in multiple phases. There is evidence suggesting that after the
primary insult, an additional brain injury is evoked by early brain injuryTampere University Hospital, PL
. This is an open access article under(EBI) and delayed cerebral ischemia (DCI). There are reports that the
development of DCI doubles the risk of poor outcome in aSAH [2,3].
Early brain injury refers to the acute effects of blood in the subarach-
noid space and the transient global ischemia caused by acute elevation
in the intracranial pressure. Delayed cerebral ischemia is amultifactorial
phenomenon involving angiographic vasospasm, microcirculatory
vasoconstriction, microvascular thrombosis, cortical spreading depolar-
ization and blood-brain barrier dysfunction. It is also thought that
processes activated during EBI contribute to the development of DCI
[2,4,5].
Various biomarkers have been examined in aSAH patients but thus
far, there are no clinically reliable biomarkers for predicting DCI orthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
56 H. Kiiski et al. / eNeurologicalSci 6 (2017) 55–62prognosis [6]. Recent ﬁndings from our group support the hypothesis
that UCH-L1 could be useful in predicting patient outcome after aSAH
although no association between UCH-L1 and DCIwas found [7]. Never-
theless, there is accumulating evidence that inﬂammation contributes
to thedevelopment of DCI [2,8–10]. Knowledge about the neural control
mechanisms of inﬂammation is accumulating rapidly [11]. A number of
cytokines and proinﬂammatory markers have been associated with a
poor outcome in aSAH [6]. Interleukin-6 (IL-6) and high-mobility
group box 1 (HMGB1) are two important inﬂammatory biomarkers;
their peripheral blood concentrations have been associated with a
poor outcome in aSAH [12–14].
It has been postulated that the inﬂammatory response displays bi-
phasic features in EBI and DCI [2,15]. The biphasic response refers to
the double-edged effects of the inﬂammatory response which can be
detrimental at some phase of the disease but alleviating at another.
The biphasic properties of multiple molecular pathways have been pro-
posed to contribute to the secondary brain injury also in other types of
acute strokes [16,17]. The putative biphasic effects of the inﬂammatory
response highlight the need for a better understanding of the mecha-
nisms and timescale of the response in aSAH. The development of reli-
able biomarkers acting as surrogates for the response could help to
achieve this goal.
The aim of the present study was to analyze the role of two bio-
markers in a group of patients with recent aSAH.We evaluatedwhether
there was any correlation between IL-6 and HMGB1 levels. By compar-
ing the concentrations of these two inﬂammatory biomarkers at the
same time points, we wanted to determine whether the changes in
their concentrations could offer more speciﬁc information about the in-
ﬂammatory pathways and possible mechanisms leading to the neural
injury developing after aSAH. In addition, we assessed their association
with neurological outcome and selected clinical conditions.2. Methods
Following the approval of the institutional ethics committee, we
conducted a prospective, observational, single-center clinical study in
Tampere University Hospital (Tampere, Finland). The hospital is one
of ﬁve tertiary referral centers in Finland serving a population of ap-
proximately 1 million inhabitants and thus providing care for all pa-
tients suffering from subarachnoid hemorrhage in the area.Fig. 1. IL6 levelsmeasuredwithin the ﬁrst 24 h after aSAH in relation to the initial clinical presen
(p = 0.002). Black circles represent outliers.The study cohort consisted of 61 consecutive aSAH patients admit-
ted to our center fromMarch2013 toDecember 2013.Written informed
consent was obtained from each patient or from their next of kin. The
time of the onset of symptoms associated with aSAH was registered
from the patient records. We excluded patients with an unknown
time of onset of symptoms as well as patients whose samples for the
IL-6 and HMGB1 assays were not collected within the ﬁrst 24 h after
the onset of symptoms. All patients were treated according to standard-
ized in-house guidelines. In total, 47 patients were considered eligible
and were thus included in the study.
The severity of the initial clinical presentationwas evaluated accord-
ing to theWorld Federation of Neurological Surgeons (WFNS) and Hunt
& Hess grading scales. The extent of the primary hemorrhage on the CT
scan was graded with Fisher scale. WFNS and Hunt & Hess were dichot-
omized into non-severe (WFNS 1–3/Hunt & Hess 1–3) or severe (WFNS
4–5 / Hunt & Hess 4–5). The Fisher grade was dichotomized into non-
severe (Fisher 1–2) or severe (Fisher 3–4). The neurological outcome
was evaluated with the modiﬁed Rankin Scale (mRS) six months after
aSAH based on a structured interview performed by telephone or dur-
ing an outpatient clinic visit. mRS was dichotomized into a favorable
outcome (mRS 0–2) or an unfavorable outcome (mRS 3–6). Detailed
categorizations of WFNS, Hunt & Hess, Fisher and mRS are presented
in a Supplementary table. Additionally, we assessed the incidence of in-
fection, which was deﬁned as the need for antimicrobial medication
during the follow-up period.
Plasma concentrations of IL-6 and HMGB1 were measured in the
samples collected at 0, 12 and 24 h after the admission, and thereafter
at every 24 h for up to ﬁve days or until the patient was transferred
from the ICU. Before the statistical analysis, the IL-6 and HMGB1 mea-
surements were divided into consecutive 24 h intervals starting from
the onset of symptoms. If IL-6 and HMGB1 were measured more than
once per interval, the mean concentration was used. In a subgroup of
22 patients who had up to ﬁve days' follow-up, we also checked if the
patient had been treated for DCI. Treatment of DCI was initiated based
on the clinical evaluation.
Blood samples were collected into EDTA-containing tubes from an
arterial cannula that had been routinely inserted for invasive blood
pressure monitoring as well as for blood sampling. After collection, the
sample was immediately delivered to the laboratory where it was cen-
trifuged for 10 min at 2000g (room temperature). After centrifugation,
the plasma was collected and kept at - 70 °C. IL-6 and HMBG1tation. Patients withmore severe clinical presentations had signiﬁcantly higher IL-6 levels
Table 1
IL-6 concentration during the ﬁrst 24 h after aSAH (n = 47).
IL-6 (pg/ml) Mean SD Median IQR p-Value
mRS 0.334
0–2 (n = 16) 9.92 6.51 8.93 4.84–13.28
3–6 (n = 31) 13.96 12.20 8.85 6.30–18.35
WFNS 0.002
1–3 (n = 28) 8.19 4.77 7.45 4.93–9.93
4–5 (n = 19) 19.07 13.58 16.30 8.88–24.05
Hunt & Hess 0.019
1–3 (n = 35) 11.21 11.04 7.70 5.13–10.63
4–5 (n = 12) 16.93 9.33 16.18 9.90–21.10
Fisher 0.051
1–2 (n = 14) 11.27 14.03 6.53 4.44–9.30
3–4 (n = 33) 13.15 9.14 10.00 7.15–17.70
Infection 0.031
Yes (n = 14) 14.84 8.63 11.40 9.34–19.38
No (n = 33) 11.63 11.46 7.50 5.00–12.35
Mann-Whitney U test was used.
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agents from eBioscience Inc. (San Diego, CA, USA) and IBL International
(Hamburg, Germany), respectively. Assay protocols are described in the
following datasheets:
http://www.ebioscience.com/media/pdf/tds/88/88-7066.pdf (IL-6)
http://www.ibl-international.com/media/catalog/product/S/T/
ST51011_IFU_EU_en_HMGB1_ELISA_V2011-01_sym4.pdf (HMGB1)
The absorbance was measured with Victor3 Multilabel Counter
(Perkin Elmer, Finland) and the results were calculated against a
standard curve using the smoothed spline method with MultiCalcTM
(Perkin Elmer, Finland).
Statistical analyses were performedwith R (version 3.3.0 for Mac OS
X). Fisher's exact test was used for the categorical variables and Mann-
Whitney U test for continuous variables. Linear regression was used for
the time interval analysis. Spearman's correlation was used to estimate
whether IL-6 and HMGB1 levels correlated
3. Results
The patients with a severe initial clinical presentation of aSAH
(WFNS 4–5/Hunt & Hess 4–5) had a higher plasma IL-6 concentration
during the ﬁrst 24 h following aSAH than the patients with a non-Fig. 2. IL6 levels measured within the ﬁrst 24 h after aSAH in relation to clinically suspected
infection during follow-up (p = 0.031). Black circles represent outliers.severe (WFNS 1–3, p = 0.002/Hunt & Hess 1–3, p = 0.019) presenta-
tion (Fig. 1, Table 1). In addition, the administration of antimicrobial
medication was associated with elevated plasma IL-6 levels (Fig. 2,
Table 1, p = 0.031). Finally, plasma IL-6 concentrations tended to be
higher in patients with severe aSAH according to Fisher scale (Fig. 3,
p = 0.051). The plasma HMGB1 concentration during the ﬁrst 24 h
after aSAH was not associated with the severity of aSAH (Table 2).
IL-6 andHMGB1 concentrationsmeasured during the ﬁrst 24 hwere
not associated with neurological outcome. The descriptive statistics for
IL-6 and HMGB1 concentrations measured during the ﬁrst 24 h after
aSAH are presented in Tables 1 and 2. The linear regression analysis re-
vealed no association between neurological outcome and IL-6 or
HMGB1 concentrations during the ﬁve-day follow-up (Fig. 4).
Plasma IL-6 and HMGB1 concentrations did not correlate with each
other at any of the time points during the ﬁve-day follow-up (Fig. 5,
Table 3). In the subgroup of those patients followed for up to ﬁve
days, IL-6 or HMGB1 concentrations during the ﬁrst 24 h did not predict
the development of DCI. In addition, the presentation of DCI did not as-
sociate with IL-6 or HMGB1 concentrations measured on day ﬁve
(Table 4).
4. Discussion
In the present study, we examined the prognostic potential and in-
terdependence of two inﬂammatory biomarkers IL-6 and HMGB1 after
aSAH.
Our study suggests that a high plasma IL-6 concentration during the
ﬁrst 24 h after aSAH is strongly associated with a severe clinical presen-
tation as well as with the development of infection during the ﬁve-day
follow-up period. However, neither IL-6 nor HMGB1 levels were associ-
ated with neurological outcome in patients suffering from aSAH. Thus,
our study failed to support the ﬁndings of some previous studies i.e.
that there would be an association between increased concentrations
of these biomarkers and poor neurological outcome. Zhu et al. claimed
that the early plasma HMGB1 concentration was associated with one-
year mortality and poor neurological outcome as determined by the
Glasgow Outcome Scale. These investigators applied stricter exclusion
criteria, for example, patients with systemic diseases such as hyperten-
sion, diabetes and chronic heart or lung disease were excluded from the
study [13]. Höllig et al. described an association between early serum
and cerebrospinal ﬂuid IL-6 concentration with poor neurologicalinfection during ICU follow-up. Early IL-6 levels are signiﬁcantly higher in patients with
Fig. 3. IL6 levels measured within the ﬁrst 24 h after aSAH in relation to the severity of aSAH in primary CT. There is a trend towards higher IL-6 levels in patients with more severe CT
ﬁndings but statistical signiﬁcance is not reached by a narrowmargin (p = 0.051). Black circles represent outliers.
Table 2
HMGB1 concentration during the ﬁrst 24 h after aSAH (n = 47).
HMGB1 (ng/ml) Mean SD Median IQR p-Value
mRS 0.486
0–2 (n = 16) 7.87 4.13 6.85 5.59–8.67
3–6 (n = 31) 6.85 2.94 6.27 4.55–8.61
WFNS 0.502
1–3 (n = 28) 6.83 2.78 6.04 5.39–7.72
4–5 (n = 19) 7.73 4.13 6.95 5.04–8.73
Hunt & Hess 0.097
1–3 (n = 35) 6.61 2.70 5.83 4.55–7.87
4–5 (n = 12) 8.87 4.62 8.04 6.34–10.10
Fisher 0.771
1–2 (n = 14) 6.95 2.34 6.85 5.52–8.78
3–4 (n = 33) 7.30 3.76 6.27 4.61–8.59
Infection 0.693
Yes (n = 14) 6.84 3.11 6.33 4.38–8.32
No (n = 33) 7.35 3.53 6.62 5.44–8.62
Mann-Whitney U test was used.
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this lack of correlation at six months to be caused partly by the high
drop-out rate (27%) after discharge [14]. Kao et al. observed an associa-
tion between early IL-6 concentration measured from the aneurysmal
oriﬁce and peripheral veins with a poor neurological outcome at one
month after aSAH. They included only patients who had undergone
endovascular coiling while patients with surgically ligated aneurysm
were excluded from the study [12]. The discrepant ﬁndings between
these previous studies and the present study may be partly explained
by the differences in the study protocols, the patient selection and the
different time-points used to measure neurological outcome. As stated
by Höllig et al. [14], it is also essential to appreciate that an elevated
IL-6 concentration is a non-speciﬁc ﬁndingwhich can reﬂect the inﬂam-
matory response to various pathologies occurring after aSAH. For exam-
ple, pneumonia is common after aSAH since patients with depressed
level of consciousness are susceptible to aspiration of gastric contents
until the airway is secured. Invasive mechanical ventilation predisposes
patients to ventilator-associated pneumonia and need for
ventriculostomy creates a possibility for ventriculitis. All of these infec-
tions may lead to increased levels of inﬂammatory biomarkers.
The secretion of IL-6 and HMGB1 as a part of the inﬂammatory re-
sponse is a complex process. One well known mechanism involves the
release of these biomarkers or rather, mediators, from monocytes and
macrophages [18–20]. In this study, an elevated IL-6 concentration
was associated with the clinical severity after aSAH. Furthermore, a
nearly statistically signiﬁcant trend for elevations in IL-6 was observed
in patients with more severe aSAH on the primary CT. On the other
hand, the HMGB1 level was not associated with either clinical severity
or the CT ﬁndings. Furthermore, the IL-6 and HMGB1 concentrations
did not correlate with each other at any time point during the ﬁve-day
follow-up. Based on these ﬁndings, it would be tempting to speculate
that the secretion of IL-6 after aSAH is mediated through a pathway un-
related to their secretion by monocytes and macrophages.
Inﬂammation has been associated with DCI [2,9] and poor outcome
after aSAH [12,14]. In our study, high concentrations of IL-6 immediately
after aSAH were associated with severe initial clinical presentation and
head CT ﬁndings. On the other hand, linear regression did not reveal any
mass increase in plasma IL-6 concentrations during follow-up and there
was no difference between IL-6 concentrations in patients with favor-
able and non-favorable neurological outcomes. Moreover, IL-6 levelswere not associated with the development of DCI. Thus, our ﬁndings
raise questions about the biphasic properties of IL-6 in inﬂammatory re-
sponse after aSAH, suggesting that the early inﬂammatory response
might not be detrimental to the patient's outcome. Plasma HMGB1, as
a late phase cytokine, was not associated with the initial severity of
aSAH or with the neurological outcome. In addition to secretion from
macrophages during inﬂammatory response, HGMB1 is also released
from cells if they die by necrosis but not when they undergo apoptosis
[21]. Apoptosis has been associatedwith EBI andDCI [2,4]. The relatively
low concentrations of HMGB1 suggest that there had not been extensive
tissue necrosis in our patients and support the hypothesis that cell death
during EBI and DCI occurs by apoptosis.
This study has some limitations. The sample size is relatively small to
make it possible to draw deﬁnite conclusions about the prognostic po-
tential of the studied biomarkers. However, the study is well powered
to rule out the possibility that there would be a signiﬁcant correlation
between IL-6 and HMGB1 levels during the ﬁve-day follow-up. We
measured IL-6 and HMGB1 in peripheral blood so the speciﬁc mecha-
nisms involved in their secretion remain elusive. Still, the lack of corre-
lation between the studied biomarkers raises interesting questions for
Fig. 4. IL-6 and HMGB1 levels for patients (n= 22)with the ICU follow-up lasting for ﬁve days (n=22). Circles represent individual patient values. Values are grouped into favorable and
non-favorable neurological outcome. Linear regression shows no signiﬁcant change between baseline values for IL-6 (mRS 0–2: p-value 0.084, beta−1.048/mRS 3–6: p-value 0.515, beta
−0.879) or HMGB1 (mRS 0–2: p-value 0.454, beta 0.183/mRS 3–6: p-value 0.776, beta 0.106) during the follow-up. Outliers are not shown.
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Fig. 5. Scatter plots displaying the correlation of individual patient values of IL-6 against those of HGMB1 at different time points during the ICU follow-up. Outliers are not shown.
60 H. Kiiski et al. / eNeurologicalSci 6 (2017) 55–62future studies investigating more speciﬁc cellular and molecular mech-
anisms of inﬂammatory response during aSAH. Here, we deﬁned infec-
tion as the use of antimicrobial medication during follow-up. Although,extreme caution is adopted in our unit with respect to the use of antimi-
crobial medication in order to avoid unnecessary treatment, it is still
possible that in a small number of patients, antibiotic therapy had
Table 3
Spearman's correlation coefﬁcients for levels of IL-6 against HMGB1 during ICU follow-up.
Timepoint Number of patients in follow-up Spearman's correlation
Day 1 47 0.171
Day 2 44 0.114
Day 3 38 −0.034
Day 4 22 −0.306
Day 5 22 0.212
61H. Kiiski et al. / eNeurologicalSci 6 (2017) 55–62been initiated for prophylaxis or simply based on strong clinical suspi-
cion for infection.
High initial IL-6 concentrations in patients with a severe clinical pre-
sentation after aSAH seem to reﬂect the intensity of the “inﬂammatory
reﬂex” [11] rather than the neuronal injury itself. Thus, the expression
of IL-6 differs from that of UCH-L1, which in our previous study was
shown to correlatewith the neuronal injury causedby aSAH [7]. Accord-
ing to recent evidence, inﬂammation seems to be a signiﬁcant contrib-
uting factor to DCI. It is plausible that inﬂammation can exert both
detrimental or beneﬁcial effects depending on the phase of the second-
ary injury process in aSAH [2]. The putative biphasic effects of the
inﬂammatory response highlight the need for clarifying the speciﬁc in-
ﬂammatory pathways and timescales in which they are activated after
aSAH. This knowledge would be of paramount importance for targeting
anti-inﬂammatory therapies to appropriate patients at valid time
points. As stated byHöllig et al. [14], a “silver-bullet” or “brain troponin”
might not exist due to the extreme complexity of physiological process-
es involved in aSAH. Our ﬁndings highlight the complexity of inﬂamma-
tory response and pathophysiology of DCI in aSAH . Therefore, future
studies should test multiple biomarkers or preferably panels of diverse
biomarkers measured at the same time-points in order to gain a better
understanding of pathophysiology underpinning the inﬂammatory re-
sponse in aSAH.5. Conclusion
High initial IL-6 values seem to reﬂect the intensity of the inﬂamma-
tory response associated with initial clinical presentation but not the
eventual brain damage per se. An early inﬂammatory response might
even be beneﬁcial since although elevated IL-6 levels were observed
in patients with a more severe initial clinical presentation, they were
not associated with neurological outcome. The lack of correlation
between IL-6 and HMGB1 raises questions about the role of macro-
phages in the process of the secretion of these inﬂammatory markers
after aSAH, instead pointing to the activation of alternative pro-
inﬂammatory pathways.Table 4
Descriptive statistics of IL-6 and HMGB1 levels in patients suffering DCI (n = 16) and
those without DCI (n = 6) in a subgroup of patients (n = 22) with at least ﬁve days'
ICU follow-up.
Mean SD Median IQR p-Value
IL-6 (pg/ml)
Day 1 DCI 12.07 8.87 8.93 6.33–12.79 0.155
NO DCI 21.73 17.56 18.35 10.94–21.75
Day 5 DCI 14.48 13.08 11.65 6.43–17.50 0.914
NO DCI 11.48 3.94 10.70 9.50–11.30
HMGB-1 (ng/ml)
Day 1 DCI 6.03 2.46 5.48 4.17–7.59 0.197
NO DCI 7.67 3.42 7.14 6.49–8.95
Day 5 DCI 6.92 3.04 6.33 5.20–9.29 0.507
NO DCI 6.07 2.70 5.50 4.83–7.56
Mann-Whitney U test was used.Funding statement
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